Recent Updates
Recently added Catalysts

hGH-ViaDerm System

Phase 1

Growth Hormone Deficiency | Small molecule | Endocrine |Teva Pharmaceutical Industries Limited|Last Updated: Sep 2, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment60
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00455260A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-DeficiencyPHASE1 COMPLETED 60Apr 1, 2007 -Sep 2, 2013 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
AE
36 days
Laboratory values
36 days
Vital signs
36 days
ECG
36 days
Patch application site reaction: Skin irritation- erythema, edema
36 days
Patch application site reaction: Pain - Visual Analogue Scale
36 days
Proportion of subjects (%) who discontinue the study
36 days
Proportion of subjects (%) who discontinue the study due to AEs
36 days
Pharmacokinetics: Somatropin exposure including Cmax, Tmax, AUC, AUC, Ke, and T1/2.
36 days
Pharmacodynamics: Human IGF-1 levels and AUC.
36 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT
Interventions
NameTypeDescription
hGH-ViaDerm™ System (hGH or somatropin)DRUGtransdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
hGH-ViaDerm™ SystemDEVICEThe hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin). The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system.
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 60 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: Ages Eligible for Study: 20 Years - 60 Years, Genders Eligible for Study: Both 1. Clinical diagnosis of Adult Growth Hormone Deficiency (AGHD) meeting one of the following criteria: * Three or more additional pituitary hormone deficiencies, based on well documented medical ...

Unlock Eligibility Criteria